NFKB1 and neoplasm: To further confirm the role of the IL1β-IL1R1 axis in activating the NF-κB pathway and inducing pro-inflammatory cytokine expression in TCM-treated SCs, we utilized two siRNAs against IL1B to knockdown IL1β levels in tumor cells, which was validated using ELISA (Figure 6F).